Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study

Alimentary Pharmacology and Therapeutics

Volumn 46, Issue 7, 2017, Pages 688-695

  Cabibbo, G ^a   Petta, S ^a   Calvaruso, V ^a   Cacciola, I ^a   Cannavo M R ^a   Madonia, S ^a   Distefano, M ^a   Larocca, L ^a   Prestileo, T ^a   Tine F ^a   Bertino, G ^a   Giannitrapani, L ^a   Benanti, F ^a   Licata, A ^a   Scalisi, I ^b   Mazzola, G ^a   Cartabellotta, F ^a   Alessi, N ^a   Barbara M ^a   Russello, M ^a   Scifo, G ^a   Squadrito, G ^a   Raimondo, G ^a   Craxi A ^a   Di Marco, V ^a   Camma C ^a   Colletti, P ^a   Corrao, S ^a   Di Lorenzo, F ^a   Fecarotta, R ^a   Sanfilippo, P ^a   Malizia, G ^a   Latteri, F ^a   Maida, M ^a   Vassallo, R ^a   Caccamo, G ^a   Maimone, S ^a   Saitta, C ^a   Mondello, L ^a   Smedile, A ^a   Ardiri, A L ^a   Montineri, A ^a   Larocca, L N ^a   Cacopardo, B ^a   Benigno, R ^a   Bellia, A ^a   Iacobello, C ^a   Davi A ^a   Di Rosolini, M A ^a   Digiacomo, A ^a   Fuduli, G ^a   Portelli, V ^a   Savalli, F ^a   Scalici, I ^a   Gioia, G ^a   Magro, A ^a   Alaimo, G ^a   Salvo, A ^a   Averna, A ^a   Lomonaco, F ^a   Quattrocchi, U ^a   Guarneri, L ^a   Maffeo, F ^a   more..

^a NONE

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CHILD PUGH SCORE; COHORT ANALYSIS; DRUG EXPOSURE; EARLY CANCER; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR VOLUME; VIROLOGY; CATHETER ABLATION; CLINICAL TRIAL; COMPLICATION; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; RISK FACTOR; TUMOR RECURRENCE;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 85028961599     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14256     Document Type: Article

References (23)

1. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176-1192.
2. Foster GR, Irving WL, Cheung MCM, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224-1231.
3. Sulkowski MS, Vargas HE, di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2015;150:419-429.
4. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719-726.
5. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727-733.
6. Pol S. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65:734-740.
7. Zavaglia C, Okolicsanyi S, Cesarini L, et al. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol. 2017;66:236-237.
8. Cheung MC, Walker AJ, Hudson BE, et al.; HCV Research UK Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65:741-747.
9. Petta S, Cabibbo G, Barbara M, et al.; Italian Liver Cancer (ITA.LI.CA) Group Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther. 2017;45:160-168.
10. Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol. 2016;65:859-860.
11. Cammà C, Cabibbo G, Craxì A. Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol. 2016;65:861-862.
12. Kolly P, Dufour JF. A strong message is needed to address the issue of HCC recurrence after DAA therapy. J Hepatol. 2016;65:1268-1269.
13. Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do 531 no harm by withdrawing treatment. J Hepatol. 2016;65:862-864.
14. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol. 2016;65:663-665.
15. Alberti A, Piovesan S. Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: fact or fiction? Liver Int. 2017;37:802-808.
16. Cabibbo G, Petta S, Barbàra M, et al. on behalf of the ITA.LI.CA Study Group. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int 2017;37:1157-1166.
17. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. European Association for the Study of the Liver; European Organisation For Research and Treatment of Cancer. J Hepatol. 2012;56:908-943.
18. Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther. 2010;32:969-983.
19. Cabibbo G, Petta S, Barbara M, et al. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J Hepatol. 2017;67:65-71.
20. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181-200.
21. Komorizono Y, Oketani M, Sako K, et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer. 2003;97:1253-1262.
22. Villa E, Critelli R, Lei B, et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut. 2016;65:861-869.
23. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51:1274-1283.